CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. Sharma A, Boelens JJ, Cancio M, Hankins JS, et al. N Engl J Med 2023;389:820-832.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sharma A, Boelens JJ, Cancio M, Hankins JS, et al. CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. N Engl J Med 2023;389:820-832.
PMID: 37646679